デフォルト表紙
市場調査レポート
商品コード
992277

ファーマコビジランスの世界市場

Pharmacovigilance

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 483 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=128.03円
ファーマコビジランスの世界市場
出版日: 2021年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 483 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界のファーマコビジランスの市場規模は、分析期間(2020年~2027年)に11.9%のCAGRで成長する見通しで、2020年の54億米ドルから、2027年には118億米ドルに達すると予測されています。

当レポートで分析されているセグメントの1つである契約アウトソーシングは、分析期間中に13.1%のCAGRで成長し、76億米ドルに達すると予測されています。

当レポートは、世界のファーマコビジランス市場について調査しており、Covid-19の影響、動向や成長要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

調査対象企業の例

  • Accenture
  • ArisGlobal
  • BioClinica Inc.
  • Capgemini
  • Cognizant
  • FMD K&L
  • IBM Corporation
  • ICON Plc
  • IQVIA
  • ITClinical
  • Laboratory Corporation of America Holdings
  • Linical Accelovance
  • Parexel International Corporation
  • TAKE Solutions Ltd.
  • United BioSource Corporation
  • Wipro Ltd.

目次

I. 調査手法

II. エグゼクティブサマリー

  • 市場概要
    • インフルエンサー市場の洞察
    • 世界市場の軌跡
    • Covid-19の影響と迫り来る世界の景気後退
  • 主要企業
  • 動向と推進要因
  • 世界市場の見通し

III. 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

IV. 競合

  • 企業プロファイル:42社
目次
Product Code: MCP22511

Abstract:

Global Pharmacovigilance Market to Reach $11.8 Billion by 2027

Amid the COVID-19 crisis, the global market for Pharmacovigilance estimated at US$5.4 Billion in the year 2020, is projected to reach a revised size of US$11.8 Billion by 2027, growing at aCAGR of 11.9% over the period 2020-2027. Contract Outsourcing, one of the segments analyzed in the report, is projected to record 13.1% CAGR and reach US$7.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the In-House segment is readjusted to a revised 10% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 15.7% CAGR

The Pharmacovigilance market in the U.S. is estimated at US$1.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2027 trailing a CAGR of 15.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.3% and 10.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.4% CAGR.

Select Competitors (Total 42 Featured) -

  • Accenture
  • ArisGlobal
  • BioClinica Inc.
  • Capgemini
  • Cognizant
  • FMD K&L
  • IBM Corporation
  • ICON Plc
  • IQVIA
  • ITClinical
  • Laboratory Corporation of America Holdings
  • Linical Accelovance
  • Parexel International Corporation
  • TAKE Solutions Ltd.
  • United BioSource Corporation
  • Wipro Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Pharmacovigilance by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Pharmacovigilance by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Pharmacovigilance by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Contract Outsourcing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Contract Outsourcing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Contract Outsourcing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for In-House by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for In-House by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for In-House by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Cardiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Respiratory Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Respiratory Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Respiratory Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Pharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Pharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Pharma Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Medical Device Manufacturers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Medical Device Manufacturers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Medical Device Manufacturers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 34: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 35: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 37: World Current & Future Analysis for Spontaneous Reporting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 38: World Historic Review for Spontaneous Reporting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: World 15-Year Perspective for Spontaneous Reporting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 40: World Current & Future Analysis for Intensified ADR Reporting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 41: World Historic Review for Intensified ADR Reporting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: World 15-Year Perspective for Intensified ADR Reporting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 43: World Current & Future Analysis for Targeted Spontaneous Reporting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 44: World Historic Review for Targeted Spontaneous Reporting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: World 15-Year Perspective for Targeted Spontaneous Reporting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 46: World Current & Future Analysis for Cohort Event Monitoring by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 47: World Historic Review for Cohort Event Monitoring by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: World 15-Year Perspective for Cohort Event Monitoring by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 49: World Current & Future Analysis for EHR Mining by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 50: World Historic Review for EHR Mining by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: World 15-Year Perspective for EHR Mining by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 52: USA Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: USA Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: USA 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 55: USA Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: USA Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: USA 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 58: USA Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: USA Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: USA 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 61: USA Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: USA Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: USA 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 64: Canada Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Canada Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Canada 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 67: Canada Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Canada Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Canada 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 70: Canada Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Canada Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: Canada 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 73: Canada Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Canada Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Canada 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 76: Japan Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Japan Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: Japan 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 79: Japan Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Japan Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Japan 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 82: Japan Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Japan Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Japan 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 85: Japan Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Japan Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Japan 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 88: China Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: China Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: China 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 91: China Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: China Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: China 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 94: China Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: China Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: China 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 97: China Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: China Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: China 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 100: Europe Current & Future Analysis for Pharmacovigilance by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 101: Europe Historic Review for Pharmacovigilance by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Europe 15-Year Perspective for Pharmacovigilance by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 103: Europe Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Europe Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Europe 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 106: Europe Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Europe Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Europe 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 109: Europe Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Europe Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: Europe 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 112: Europe Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Europe Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: Europe 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 115: France Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: France Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: France 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 118: France Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: France Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: France 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 121: France Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 122: France Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 123: France 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 124: France Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 125: France Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 126: France 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 127: Germany Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Germany Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 129: Germany 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 130: Germany Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Germany Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 132: Germany 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 133: Germany Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Germany Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 135: Germany 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 136: Germany Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Germany Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 138: Germany 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 139: Italy Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Italy Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 141: Italy 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 142: Italy Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Italy Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 144: Italy 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 145: Italy Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Italy Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 147: Italy 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 148: Italy Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Italy Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 150: Italy 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 151: UK Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 152: UK Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 153: UK 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 154: UK Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 155: UK Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 156: UK 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 157: UK Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 158: UK Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 159: UK 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 160: UK Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 161: UK Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 162: UK 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 163: Spain Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Spain Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 165: Spain 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 166: Spain Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Spain Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 168: Spain 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 169: Spain Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Spain Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 171: Spain 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 172: Spain Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 173: Spain Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 174: Spain 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 175: Russia Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Russia Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 177: Russia 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 178: Russia Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 179: Russia Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 180: Russia 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 181: Russia Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Russia Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 183: Russia 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 184: Russia Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 185: Russia Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 186: Russia 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 187: Rest of Europe Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 188: Rest of Europe Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 189: Rest of Europe 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 190: Rest of Europe Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 191: Rest of Europe Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 192: Rest of Europe 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 193: Rest of Europe Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 194: Rest of Europe Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 195: Rest of Europe 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 196: Rest of Europe Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 197: Rest of Europe Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 198: Rest of Europe 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 199: Asia-Pacific Current & Future Analysis for Pharmacovigilance by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 200: Asia-Pacific Historic Review for Pharmacovigilance by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 201: Asia-Pacific 15-Year Perspective for Pharmacovigilance by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 202: Asia-Pacific Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Asia-Pacific Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 204: Asia-Pacific 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 205: Asia-Pacific Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 206: Asia-Pacific Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 207: Asia-Pacific 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 208: Asia-Pacific Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 209: Asia-Pacific Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 210: Asia-Pacific 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 211: Asia-Pacific Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 212: Asia-Pacific Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 213: Asia-Pacific 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 214: Australia Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 215: Australia Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 216: Australia 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 217: Australia Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 218: Australia Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 219: Australia 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 220: Australia Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 221: Australia Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 222: Australia 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 223: Australia Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 224: Australia Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 225: Australia 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 226: India Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 227: India Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 228: India 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 229: India Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 230: India Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 231: India 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 232: India Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 233: India Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 234: India 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 235: India Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 236: India Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 237: India 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 238: South Korea Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 239: South Korea Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 240: South Korea 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 241: South Korea Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 242: South Korea Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 243: South Korea 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 244: South Korea Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 245: South Korea Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 246: South Korea 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 247: South Korea Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 248: South Korea Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 249: South Korea 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 250: Rest of Asia-Pacific Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 251: Rest of Asia-Pacific Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 252: Rest of Asia-Pacific 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 253: Rest of Asia-Pacific Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 254: Rest of Asia-Pacific Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 255: Rest of Asia-Pacific 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 256: Rest of Asia-Pacific Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 257: Rest of Asia-Pacific Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 258: Rest of Asia-Pacific 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 259: Rest of Asia-Pacific Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 260: Rest of Asia-Pacific Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 261: Rest of Asia-Pacific 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 262: Latin America Current & Future Analysis for Pharmacovigilance by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 263: Latin America Historic Review for Pharmacovigilance by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 264: Latin America 15-Year Perspective for Pharmacovigilance by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 265: Latin America Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 266: Latin America Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 267: Latin America 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 268: Latin America Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 269: Latin America Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 270: Latin America 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 271: Latin America Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 272: Latin America Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 273: Latin America 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 274: Latin America Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 275: Latin America Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 276: Latin America 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 277: Argentina Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 278: Argentina Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 279: Argentina 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 280: Argentina Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 281: Argentina Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 282: Argentina 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 283: Argentina Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 284: Argentina Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 285: Argentina 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 286: Argentina Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 287: Argentina Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 288: Argentina 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 289: Brazil Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 290: Brazil Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 291: Brazil 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 292: Brazil Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 293: Brazil Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 294: Brazil 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 295: Brazil Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 296: Brazil Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 297: Brazil 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 298: Brazil Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 299: Brazil Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 300: Brazil 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 301: Mexico Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 302: Mexico Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 303: Mexico 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 304: Mexico Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 305: Mexico Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 306: Mexico 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 307: Mexico Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 308: Mexico Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 309: Mexico 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 310: Mexico Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 311: Mexico Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 312: Mexico 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 313: Rest of Latin America Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 314: Rest of Latin America Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 315: Rest of Latin America 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 316: Rest of Latin America Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 317: Rest of Latin America Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 318: Rest of Latin America 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 319: Rest of Latin America Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 320: Rest of Latin America Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 321: Rest of Latin America 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 322: Rest of Latin America Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 323: Rest of Latin America Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 324: Rest of Latin America 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 325: Middle East Current & Future Analysis for Pharmacovigilance by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 326: Middle East Historic Review for Pharmacovigilance by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 327: Middle East 15-Year Perspective for Pharmacovigilance by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 328: Middle East Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 329: Middle East Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 330: Middle East 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 331: Middle East Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 332: Middle East Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 333: Middle East 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 334: Middle East Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 335: Middle East Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 336: Middle East 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 337: Middle East Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 338: Middle East Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 339: Middle East 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 340: Iran Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 341: Iran Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 342: Iran 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 343: Iran Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 344: Iran Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 345: Iran 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 346: Iran Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 347: Iran Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 348: Iran 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 349: Iran Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 350: Iran Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 351: Iran 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 352: Israel Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 353: Israel Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 354: Israel 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 355: Israel Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 356: Israel Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 357: Israel 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 358: Israel Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 359: Israel Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 360: Israel 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 361: Israel Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 362: Israel Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 363: Israel 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 364: Saudi Arabia Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 365: Saudi Arabia Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 366: Saudi Arabia 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 367: Saudi Arabia Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 368: Saudi Arabia Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 369: Saudi Arabia 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 370: Saudi Arabia Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 371: Saudi Arabia Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 372: Saudi Arabia 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 373: Saudi Arabia Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 374: Saudi Arabia Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 375: Saudi Arabia 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 376: UAE Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 377: UAE Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 378: UAE 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 379: UAE Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 380: UAE Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 381: UAE 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 382: UAE Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 383: UAE Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 384: UAE 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 385: UAE Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 386: UAE Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 387: UAE 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 388: Rest of Middle East Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 389: Rest of Middle East Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 390: Rest of Middle East 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 391: Rest of Middle East Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 392: Rest of Middle East Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 393: Rest of Middle East 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 394: Rest of Middle East Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 395: Rest of Middle East Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 396: Rest of Middle East 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 397: Rest of Middle East Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 398: Rest of Middle East Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 399: Rest of Middle East 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 400: Africa Current & Future Analysis for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 401: Africa Historic Review for Pharmacovigilance by Service Provider - Contract Outsourcing and In-House Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 402: Africa 15-Year Perspective for Pharmacovigilance by Service Provider - Percentage Breakdown of Value Sales for Contract Outsourcing and In-House for the Years 2012, 2020 & 2027
    • TABLE 403: Africa Current & Future Analysis for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 404: Africa Historic Review for Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 405: Africa 15-Year Perspective for Pharmacovigilance by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiology, Respiratory Systems, Other Therapeutic Areas, Oncology and Neurology for the Years 2012, 2020 & 2027
    • TABLE 406: Africa Current & Future Analysis for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 407: Africa Historic Review for Pharmacovigilance by End-Use - Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 408: Africa 15-Year Perspective for Pharmacovigilance by End-Use - Percentage Breakdown of Value Sales for Pharma Companies, Biotech Companies, Medical Device Manufacturers and Other End-Uses for the Years 2012, 2020 & 2027
    • TABLE 409: Africa Current & Future Analysis for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 410: Africa Historic Review for Pharmacovigilance by Type - Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 411: Africa 15-Year Perspective for Pharmacovigilance by Type - Percentage Breakdown of Value Sales for Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 42